Recent Updates
Recently added Catalysts
BBIO Positive Sentiment Score: 75/100

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Monday, June 3, 2024 1 min read
Key Takeaway: BridgeBio Pharma, Inc. is set to host a call on June 4, 2024, to discuss results from Month 12 and Month 18 of Cohort 5 of the PROPEL 2 Phase 2 trial. The study focuses on the investigational oral therapy infigratinib for treating achondroplasia in children. Dr. Ravi Savarirayan from Murdoch Children's Research Institute will be among the presenters, highlighting the collaboration with leading experts in the field. A replay of the call will be available for 90 days post-event.

Market Sentiment Analysis

POSITIVE FACTORS

  • BridgeBio is providing important results from the Phase 2 trial, which could indicate progress in treating achondroplasia.
  • The involvement of a prominent expert in the field, Dr. Ravi Savarirayan, adds credibility and interest to the findings.
  • The live call allows for direct engagement with stakeholders and fosters transparency.

Full Press Release Details

PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children’s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a call on June 4, 2024, at 8:00 am ET to share results from Month 12 and Month 18 from Cohort 5 of PROPEL 2, a Phase 2 trial of the investigational oral therapy infigratinib in children with achondroplasia.
To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
contact@bridgebio.com

Frequently Asked Questions

What is the PROPEL 2 trial about?

PROPEL 2 is a Phase 2 trial studying infigratinib in children with achondroplasia.

When will the PROPEL 2 results be shared?

The results will be shared on June 4, 2024, at 8:00 am ET.

Who is the lead investigator for PROPEL 2?

Ravi Savarirayan, M.D., Ph.D., from Murdoch Children’s Research Institute is the lead investigator.

How can I access the live webcast of the results?

Visit the 'Events' page in the Investors section of the BridgeBio website.

Will the webcast be available later?

Yes, a replay of the webcast will be available for 90 days post-event.

Tags: BBIO Viatris Investor Conferences Healthcare BridgeBio achondroplasia infigratinib Phase 2 trial Palo Alto
Last updated: Jun 3, 2024